The aim of the study was to assess the impact of employing the KHA-200 hemoperfusion device in conjunction with hemodialysis therapy in the elimination of serum solutes among maintenance hemodialysis (MHD) patients.A total of ninety-two MHD patients from our hospital's hemodialysis center were judiciously chosen and allocated randomly into two groups: the conventional hemodialysis group, serving as the control group, and the group utilizing the KHA-200 hemoperfusion device in combination with hemodialysis, denoted as the experimental group, in a 1:1 ratio. We compared variations in serum solute indices, including blood urea nitrogen, creatinine, potassium, calcium, phosphorus, high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), β2-microglobulin (β2-MG), parathyroid hormone (PTH), homocysteine (Hcy), albumin, both prior to and post-treatment. Meanwhile, a comparison of the serum solute clearance rates in the two groups was performed.Following treatment, both groups exhibited substantial reductions in blood urea nitrogen, creatinine, uric acid, potassium, phosphorus, PTH, and Hcy (p < 0.001). There were no statistically significant distinctions between the two groups in terms of urea nitrogen, creatinine, uric acid, and potassium clearance (p > 0.05). Conversely, the experimental group demonstrated a significant effect on the elimination of IL-6 and β2-MG (p < 0.001). Furthermore, the experimental group's performance in reducing blood phosphorus, PTH, IL-6, β2-MG, and Hcy was significantly superior to that of the control group (p < 0.05). Moreover, the reduction in systolic blood pressure in the experimental group was better than in the control group.Employing the KHA-200 hemoperfusion device in tandem with hemodialysis excels in removing blood phosphorus and certain medium-sized uremic toxins, including PTH, IL-6, β2-MG, and Hcy, surpassing the performance of conventional hemodialysis.© 2025 The Author(s). Published by S. Karger AG, Basel.